Overall, these results suggest that the loss of Shank3a does not appear to be a secondary consequence of Aβ/tau neuropathology, and may rather occur before or in parallel with the accumulation of classical AD neuropathology. This evidence concerns the gene MAPT and Alzheimer disease.